The purpose is to find out how much medication is in breastmilk after intake.
This will help us determine the daily dose a child could potentially be exposed to during breastfeeding, if the nursing mother must take this medicinal product.
誰が参加できますか
This study is seeking healthy breastfeeding female participants.
Condition
Healthy lactating women who agree to temporally interrupt breastfeeding their child for 4.5 days
Age
18 - 55
Sex
Female
Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.
Additional eligibility criteria
SPECIFIC EXCLUSIONS FROM THIS STUDY
You may not take part in this study if:
• You have received a COVID-19 vaccine within 7 days before screening or admission, or you are to be vaccinated with a COVID-19 vaccine at any time during your stay at the PCRU.
• You are not a woman, in good health, breastfeeding or expressing breastmilk and having given birth at least 12 weeks ago.
• You are pregnant.
• You do not want to temporarily discontinue breastfeeding your child for a total period of 4.5 days, starting from evening of the day before the administration of the study drug (Day -1) up to the next day after you leave the PCRU (Day 5).
• You do not agree to using a breast pump regularly or to not giving that breastmilk to your child during this period.
• You have not chosen another feeding method for your child during the 4.5 days when he/she will not be able to take your breastmilk.
• You are not able to express at least 14 mL of breastmilk over a 2-hour interval prior to Day 1
• Your infant cannot be fed successfully from a bottle or other alternative methods (such as a cup, syringe, finger-feeder, etc.) prior to the start of the study.
• Your infant cannot tolerate infant formula for the scenario that there is not sufficient stored breastmilk to cover the duration of the study e.g. when nursing is restricted.
COMMON EXCLUSIONS TO MOST OF THE STUDIES
You may not take part in this study if:
• You are outside of the age limits (18-55 years) or weight limits (minimum of 50 kg), or you are outside of the limits of the Body Mass Index (minimum 17.5 kg/m2 ).
• You are regularly taking medications or you are suffering from a chronic illness.
• You have an illness or you have received treatment that may affect absorption of the medicines (for example a gastrectomy).
• You are suffering from asthma or from any allergy to a medicine.
• You are suffering from symptomatic or seasonal allergies (hay fever) and require treatment.
• You smoke more than 5 cigarettes a day or consume an equivalent quantity of tobacco / nicotine containing products.
• You have taken part in another clinical study involving investigational medicines within the last 30 days.
• You have given blood or constituent elements of blood (platelets) during the two months preceding the study or you intend to be a donor in the two months following the end of the study (Red Cross standard to guarantee blood cells regeneration). Giving plasma is allowed.
• You have taken or you are taking drugs.
• You think you are at risk of being infected with the AIDS virus, hepatitis B or C.
• You have a history of regular alcohol consumption exceeding 14 drinks/week (1 drink = 90 mL of wine or 240 mL of beer or 30 mL of spirit).
実施項目
The study is planned to last for approximately 9 weeks.
Several examinations or procedures will be required in connection with the study:
- A screening examination, during which you will sign a COVID ICD and the study ICD;
- COVID-19 assessments during residence in the PCRU
- One treatment period organized of 5 days and 4 nights in the PCRU (from Day -1 to Day 4).
- The follow-up phone call will take place 28 to 35 days after the last administration of the study medicine.
You will not personally derive any benefit from your participation in this study, but the results obtained could be very important for the development of medicines and treatments which will benefit other people.
Long-term follow-up
a follow-up call at the end of the study
How long is the study?
Approximately 9 weeks
compensation
€ 1.670 upon completion of the study, €120 Covid and transportation fees
参加に関心が
ありますか。
この治験についての詳しい情報:
0800.99.256 (フリーダイヤル:ベルギーから)、00800.26.36.26.36(フリーダイヤル:イギリス、フランス、ドイツ、オランダから)、+32.25.66.78.46(有料ダイヤル:上記以外の国から)に電話し、担当者に詳細をお問い合わせください。または、以下の登録フォームに入力してご送信ください。
「個人情報」とは名前、生年月日、電話番号、健康状態や病状など、一個人としてのあなたに関する情報を意味します。登録フォームに登録される際に当社と共有される個人情報は、医療アンケートや関連資料を送信するためにPCRUブリュッセルによって収集されます。
あなたの個人情報は、厳密に機密扱いで取り扱われ、適応されるすべての法律、特に治験に関するEUとベルギーの法律およびEUとベルギーの個人情報保護に関する法律に準拠して処理されます。
個人情報保護は私たち治験ユニットにとっても非常に重要です、そのため、https://privacycenter.pfizer.com/en/belgiumよりプライバシーに関する通知をお読みください。